Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Roche's Tominersen?
Tominersen is an antisense oligonucleotide commercialized by Roche, with a leading Phase III program in Huntington Disease. According to Globaldata,...
Data Insights
Tominersen by F. Hoffmann-La Roche for Huntington Disease: Likelihood of Approval
Tominersen is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Huntington Disease. According to GlobalData,...